Myriad Genetics Plunges 43.4% Amid Contrasting Analyst Views

On April 1, 2025, Myriad Genetics experienced a significant drop of 43.4% in pre-market trading, marking a substantial decline in its stock value.

Piper Sandler upgraded Myriad Genetics from a "neutral" rating to an "overweight" rating, while also increasing their target price for the stock from $11.50 to $12.50. This move reflects a positive outlook on the company's future performance and potential for growth.

J.P. Morgan analyst Rachel Vatnsdal maintained a sell rating for Myriad Genetics, keeping the target price at $20. This contrasting view suggests a more cautious stance on the company's prospects, highlighting the differing opinions among analysts.

Myriad Genetics has secured two new patents from the U.S. Patent and Trademark Office, which are expected to advance the company's tumor genomic testing capabilities. These patents are likely to enhance Myriad Genetics' competitive position in the genetic testing market, potentially driving future growth and innovation.